



Attorney Docket No.: 5694.200-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Flodgaard et al.

Serial No.: 09/559,764

Group Art Unit: 1644

Filed: April 27, 2000

Examiner: Jessica H. Roark

Confirmation No: 2707

For: Inhibition Of Bradykinin Release

**AMENDMENT FEE TRANSMITTAL**

Commissioner for Patents  
Washington, DC 20231

Sir:

Transmitted herewith is an Amendment for the above-identified application in response to the Final Office Action mailed December 6, 2002.

It is respectfully requested that the time for response to the Final Office Action dated September 6, 2002 be extended for a period of three (3) months from December 6, 2002 to March 6, 2003. The required fee for the extension is estimated to be \$930.

No additional claims fee is required.

In the event that an extension of time is required, Applicants hereby petition for such extension of time. The Commissioner of Patents is authorized to charge the required fee, if applicable, to Deposit Account No. 14-1447.

\$1644


#18/C  
JM  
4/5/03

**RECEIVED**  
MAR 19 2003  
TECH CENTER 1600/2900

Please charge the required extension fees, estimated to be \$930, to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: March 6, 2003



---

Cheryl H. Agris, Reg. No. 34,086  
Outside Counsel for  
Novo Nordisk Pharmaceuticals, Inc.  
100 College Road West  
Princeton, NJ 08740  
(609) 919-7840



Attorney Docket No.: 5694.200-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Flodgaard et al.

Application No.: 09/559,764

Group Art Unit: 1644

Filed: April 27, 2000

Examiner: J. Roark

For: Inhibition Of Bradykinin Release

**RECEIVED**  
MAR 19 2003  
TECH CENTER 1600/2900

**AMENDMENT UNDER 37 C.F.R. 1.111**

Commissioner for Patents  
Washington, DC 20231

Sir:

In response to the Office Action dated September 6, 2003, please consider the following amendments and remarks.

**IN THE SPECIFICATION**

Please amend the specification as follows, with a marked up version attached hereto:

Please amend the paragraph on page 10, lines 10-13 to read as follows:

C1  
Figures 5A and 5B shows inhibition of bradykinin- and HBP-induced increase in EC permeability with monoclonal antibody MBK3 to bradykinin. Bradykinin (100 nM; Figure 5a) or HBP (75 µg/ml; Figure 5b) is administered at time zero to the lamina side of EC monolayers pre-incubated with mAb MBK3 (40 µg/ml).

Please amend the paragraph on page 11, lines 2-6 to read as follows:

C2  
Figures 11 A-C show Saturation of native HBP, [R23S,F25E]HBP, and [G175Q]HBP